Novo Nordisk raises 2024 outlook as company races to boost output of Wegovy weight-loss drug

Novo Nordisk reported better-than-expected first-quarter profits on Thursday as it looks to fend off competition from rival Eli Lilly

Related Keywords

United States ,Denmark ,Canada ,Poland ,Spain ,Germany ,United Kingdom ,Britain ,Danish ,Eli Lilly ,Karsten Munk Knudsen ,Markus Manns ,Lars Fruergaard Jorgensen ,Novo Holdings ,Union Investment ,Novo Nordisk ,Jyske Bank ,Us Federal Trade Commission ,Reuters ,Log Increate Free ,Fruergaard Jorgensen ,Chief Financial Officer Karsten Munk Knudsen ,Trade Commission ,Scent ,Novo ,Wegovy ,Deal ,Company ,Competition ,